Intrinsic disorder in nuclear hormone receptors.

Nucleolar targeting: the hub of the matter. EMBO Rep (2009) 1.82

Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev (2012) 1.11

Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01

Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97

Roles of intrinsic disorder in protein-nucleic acid interactions. Mol Biosyst (2011) 0.96

Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors. J Biol Chem (2011) 0.96

Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer (2010) 0.93

The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos (2009) 0.87

Regulation of the structurally dynamic N-terminal domain of progesterone receptor by protein-induced folding. J Biol Chem (2013) 0.82

Structural diversity and evolution of the N-terminal isoform-specific region of ecdysone receptor-A and -B1 isoforms in insects. BMC Evol Biol (2010) 0.82

Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci (2014) 0.82

Understanding nuclear receptors using computational methods. Drug Discov Today (2009) 0.80

Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting. Asian J Androl (2016) 0.77

Research resource: EPSLiM: ensemble predictor for short linear motifs in nuclear hormone receptors. Mol Endocrinol (2014) 0.76

The pERK of being a target: Kinase regulation of the orphan nuclear receptor ERRγ. Receptors Clin Investig (2015) 0.76

The mechanism of enterohepatic circulation in the formation of gallstone disease. J Membr Biol (2014) 0.75

The large-scale organization of metabolic networks. Nature (2000) 27.57

Specificity and stability in topology of protein networks. Science (2002) 21.07

Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09

Intrinsic disorder and protein function. Biochemistry (2002) 8.54

Intrinsically disordered protein. J Mol Graph Model (2001) 8.54

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 8.33

Intrinsic disorder in cell-signaling and cancer-associated proteins. J Mol Biol (2002) 5.64

Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36

Pathway mapping tools for analysis of high content data. Methods Mol Biol (2007) 4.87

Evolution of hormone-receptor complexity by molecular exploitation. Science (2006) 4.65

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A (2001) 4.58

Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature (1995) 3.32

Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS Comput Biol (2006) 3.23

LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol (2006) 3.11

Intrinsic disorder in transcription factors. Biochemistry (2006) 3.06

The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell (1993) 2.95

A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell (2003) 2.85

The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell (2000) 2.77

Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell (2005) 2.69

Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Proc Natl Acad Sci U S A (2006) 2.57

Evolutionary rate heterogeneity in proteins with long disordered regions. J Mol Evol (2002) 2.46

Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell (2000) 2.33

Orphan nuclear receptors: shifting endocrinology into reverse. Science (1999) 2.32

Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor. J Mol Endocrinol (1997) 2.29

Identification and functions of usefully disordered proteins. Adv Protein Chem (2002) 2.23

Optimizing long intrinsic disorder predictors with protein evolutionary information. J Bioinform Comput Biol (2005) 2.20

Ecdysone receptors and their biological actions. Vitam Horm (2000) 2.18

Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect (2004) 2.16

Transcription factors 3: nuclear receptors. Protein Profile (1995) 2.02

Ligand binding was acquired during evolution of nuclear receptors. Proc Natl Acad Sci U S A (1997) 1.94

Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci (2000) 1.77

Human transcription factors contain a high fraction of intrinsically disordered regions essential for transcriptional regulation. J Mol Biol (2006) 1.71

Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos (2001) 1.70

Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol (2002) 1.67

Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol (2003) 1.57

Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol (2005) 1.55

Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J Biol Chem (2004) 1.44

Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res (2006) 1.42

International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev (2006) 1.38

Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33

Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J (2003) 1.31

Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. Environ Health Perspect (2004) 1.30

Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J (2005) 1.27

Conservation of intrinsic disorder in protein domains and families: II. functions of conserved disorder. J Proteome Res (2006) 1.27

Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. J Mol Biol (2006) 1.22

Illuminating drug discovery with biological pathways. FEBS Lett (2005) 1.22

Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain. J Biol Chem (2005) 1.21

The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Res (2003) 1.20

Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol (2007) 1.17

Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept (2005) 1.17

The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties. J Biol Chem (2001) 1.15

Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab (2005) 1.14

Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14

Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nucl Recept Signal (2007) 1.08

Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08

Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. J Steroid Biochem Mol Biol (2007) 1.06

Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06

Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry (2008) 1.06

The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res (1999) 1.04

Farnesoid X receptor: from structure to potential clinical applications. J Med Chem (2005) 1.02

Distinct amino acid residues may be involved in coactivator and ligand interactions in hepatocyte nuclear factor-4alpha. J Biol Chem (2005) 1.01

The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J Biol Chem (2003) 1.01

Sequence-specific deoxyribonucleic acid (DNA) recognition by steroidogenic factor 1: a helix at the carboxy terminus of the DNA binding domain is necessary for complex stability. Mol Endocrinol (2005) 1.00

Retinoid X receptor and retinoic acid response in the marine sponge Suberites domuncula. J Exp Biol (2003) 1.00

Intrinsic disorder in yeast transcriptional regulatory network. Proteins (2007) 0.98

Orphan nuclear receptor modulators. Curr Top Med Chem (2003) 0.95

High-resolution solution structure of the retinoid X receptor DNA-binding domain. J Mol Biol (1998) 0.94

Structural and functional characterization of a novel type of ligand-independent RXR-USP receptor. EMBO J (2007) 0.93

A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab Dispos (2004) 0.92

Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol Endocrinol (2003) 0.91

Intrinsically disordered loops inserted into the structural domains of human proteins. J Mol Biol (2005) 0.91

Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J Mol Biol (2003) 0.90

Rapid divergence of the ecdysone receptor in Diptera and Lepidoptera suggests coevolution between ECR and USP-RXR. Mol Biol Evol (2003) 0.89

Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr Opin Pharmacol (2005) 0.88

The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics. Biochem Soc Trans (2006) 0.85

The role of hinge domain in heterodimerization and specific DNA recognition by nuclear receptors. Mol Cell Endocrinol (2001) 0.82

Evolutionary constraint networks in ligand-binding domains: an information-theoretic approach. Pac Symp Biocomput (1999) 0.78

The toxicogenomics of nuclear receptor agonists. Curr Opin Chem Biol (2003) 0.77

A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett (2005) 1.71

Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68

Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 1.40

Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39

Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today (2012) 1.39

Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37

Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26

Mobile apps for chemistry in the world of drug discovery. Drug Discov Today (2011) 1.26

Methods for predicting human drug metabolism. Adv Clin Chem (2007) 1.24

A quality alert and call for improved curation of public chemistry databases. Drug Discov Today (2011) 1.22

Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21

New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20

Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood (2007) 1.18

The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17

A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16

Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15

Reaching out to collaborators: crowdsourcing for pharmaceutical research. Pharm Res (2010) 1.14

Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14

A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14

Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13

Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12

Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09

Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09

Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol (2003) 1.08

Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08

Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07

Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today (2013) 1.07

Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06

Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today (2012) 1.05

Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2009) 1.04

Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos (2010) 1.04

Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04

Time for cooperation in health economics among the modelling community. Pharmacoeconomics (2010) 1.04

Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01

Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01

Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01

Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99

Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99

PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98

Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97

Parallel worlds of public and commercial bioactive chemistry data. J Med Chem (2014) 0.97

Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev (2002) 0.97

Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96

Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol (2006) 0.96

Redefining Cheminformatics with Intuitive Collaborative Mobile Apps. Mol Inform (2012) 0.96

Comprehensive computational assessment of ADME properties using mapping techniques. Curr Drug Discov Technol (2005) 0.95

Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharm Res (2012) 0.94

Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94

Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93

Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J Chem Inf Model (2013) 0.93

Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol (2010) 0.93

Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92

Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen (2002) 0.91

Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev (2002) 0.90

Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today (2005) 0.90

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res (2006) 0.90

Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm (2010) 0.90

Computational models for neglected diseases: gaps and opportunities. Pharm Res (2013) 0.89

Troubleshooting computational methods in drug discovery. J Pharmacol Toxicol Methods (2010) 0.89

The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem (2011) 0.89

Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos (2004) 0.88

Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res (2008) 0.88

The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos (2009) 0.87

A retrospective randomized study of asthma control in the US: results of the CHARIOT study. Curr Med Res Opin (2008) 0.87

Alternative business models for drug discovery. Drug Discov Today (2011) 0.87

Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol (2013) 0.87

Why open drug discovery needs four simple rules for licensing data and models. PLoS Comput Biol (2012) 0.86

Modeling of active transport systems. Adv Drug Deliv Rev (2002) 0.86

Computational prediction and validation of an expert's evaluation of chemical probes. J Chem Inf Model (2014) 0.84

Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors. Pharm Res (2009) 0.84

Computational mapping tools for drug discovery. Drug Discov Today (2009) 0.83

Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies. Biochem Pharmacol (2010) 0.83

Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem (2009) 0.83

Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier. Drug Metab Dispos (2013) 0.83

Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos (2002) 0.83

Classification of metabolites with kernel-partial least squares (K-PLS). Drug Metab Dispos (2006) 0.82

Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Ther Drug Monit (2009) 0.82

Halogenated ligands and their interactions with amino acids: implications for structure-activity and structure-toxicity relationships. J Mol Graph Model (2008) 0.82

Applications and limitations of in silico models in drug discovery. Methods Mol Biol (2012) 0.81

Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro. Aquat Toxicol (2010) 0.81

Targeting drug transporters - combining in silico and in vitro approaches to predict in vivo. Methods Mol Biol (2010) 0.81

Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates. Drug Metab Dispos (2004) 0.81

Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database. Environ Health Perspect (2010) 0.80

Understanding nuclear receptors using computational methods. Drug Discov Today (2009) 0.80

Novel diaryl ureas with efficacy in a mouse model of malaria. Bioorg Med Chem Lett (2012) 0.79

Ligand- and structure-based pregnane X receptor models. Methods Mol Biol (2012) 0.78

Competitive collaboration in the pharmaceutical and biotechnology industry. Drug Discov Today (2009) 0.78

A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol (2010) 0.78

The PXR crystal structure: the end of the beginning. Trends Pharmacol Sci (2002) 0.78

Combined computational metabolite prediction and automated structure-based analysis of mass spectrometric data. Toxicol Mech Methods (2008) 0.78

Activation of a tunicate (Ciona intestinalis) xenobiotic receptor orthologue by both natural toxins and synthetic toxicants. Toxicon (2011) 0.78

Accessing, using, and creating chemical property databases for computational toxicology modeling. Methods Mol Biol (2012) 0.77

Improving the drug selection and development process for combination devices. Drug Discov Today (2007) 0.77

Prediction of human drug metabolizing enzyme induction. Curr Drug Metab (2003) 0.76

Machine Learning Models for Estrogen Receptor Bioactivity and Endocrine Disruption Prediction. Environ Sci Technol (2020) 0.75

A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors. ACS Infect Dis (2017) 0.75